Protein Therapeutics Market Growth Analysis By Top Key Players: Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd. and more

According to a report by Allied Market Research, the world for protein therapeutics market in 2016 was $ 140.19 billion, according to "By products and Applications by Protein Therapeutics Market - Global Opportunity Analysis and Industry Outlook, 2017-2023" 6.5% to reach $ 217,591 million by 2023. The Monoclonal Antibody Products sector ranked first in market share in 2016.

Therapeutic proteins are an important class of drugs that provide services to patients in need of new treatments. Approved recombinant protein therapeutics have been developed to treat a variety of clinical signs, including cancer, genetic disorders, infectious diseases and metabolic disorders.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/60?utm_source=sy

The report provides extensive competitive analysis and profiles of key market players, such as
• Abbott Laboratories
• Amgen Inc.
• Baxter International Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co. Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi

Other players (profiles not included in the report) in the value chain analysis include, Biogen, Inc., CSL Behring, and Genentech, Inc.

Key factors driving the growth of the worldwide protein therapeutics market include the introduction and adoption of new plasma induction therapies, the proliferation of chronic and life-threatening diseases, and public awareness of the high efficiency of protein therapeutics. However, the high cost of protein therapy and complex redemption scenarios hamper market growth.

Conversely, increased protein therapeutics and new indications for untapped emerging markets are expected to provide manufacturers with a favorable opportunity in this industry.

The metabolic disorders application generated the highest revenue of $27,837 million in 2016, and is anticipated to continue this trend in the future. This is attributed to the requirement for quality drugs and versatile therapies for disease treatment, especially diabetes. Cancer application is anticipated to grow at the highest CAGR of 8.2% from 2017 to 2023.

North America held the highest market share of $72,899 million in 2016, owing to high prevalence rate of cancer and other chronic diseases, owing to rise in adoption of these drugs and increase in awareness about protein therapeutics. Asia-Pacific is expected to grow at the highest CAGR of 7.6% during the forecast period, owing to rapid industrialization in the area, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.

Make an Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/60?utm_source=sy

Key Findings of the Protein Therapeutics Market:
• The monoclonal antibody segment is anticipated to grow at the highest CAGR from 2017 to 2023.
• The cancer application segment is expected to witness the highest growth rate during the forecast period.
• Metabolic disease application segment is anticipated to occupy the largest share in the protein therapeutics market.
• North America dominated the global protein therapeutics market, and is projected to grow at a CAGR of 6.1%.

Access Full Summery @ https://www.alliedmarketresearch.com/protein-therapeutics-market?utm_source=sy

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.